Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents

NCT00099333 · Completed

Last updated 2026-05-28

This clinical trial tests whether replacing insulin with exenatide is safe in adults with type 2 diabetes who are already taking insulin and other diabetes medications.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 49 people

Who can join Ages 35–70 · all sexes

Timeline Started 2004-02 · est. completion 2005-08

Where 5 sites · United States

What this study is testing ClinicalTrials.gov NCT00099333 ↗

Description as written by the study sponsor.

This study will look at the safety of substituting exenatide for insulin in patients with type 2 diabetes who are currently taking insulin and oral antidiabetic agent(s).

Treatments tested

exenatide also known as synthetic exendin-4, AC2993, Byetta Drug

Exenatide 5 mcg subcutaneously injected twice daily for 4 weeks; then 10 mcg subcutaneously injected twice daily for 12 weeks.
Insulin Drug

Insulin will be taken according to the subject's current regimen

Main thing measured	Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 16
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00099333 ↗